Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 22,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference.
Podcast: Accelerated approvals – what’s next, confirmatory trials, access, and pricing August 5, 2024 5:18pm
Focusing on cell and gene therapies, this podcast discusses the use of accelerated approvals for fast tracking promising novel medicines through clinical development to registration.
View this post
De-risking Drug Development | Episode 3: Plan how to get to market quickly, post proof-of-concept July 16, 2024 10:50am
De-risking Drug Development is a five-part podcast series that explores the business-critical decisions that take place at each stage of the drug development process. We know that novel therapies often don’t meet their revenue expectations, but through informed decision-making, you can minimize risk and maximize the probability of commercial success.
This is episode three, where we discuss how to accelerate development and opportunities to differentiate your product through innovative and adap...
View this post
Enabling Successful Sites Ep. 2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training June 28, 2024 10:34am
The second episode of our ‘Enabling Successful Sites’ series features a discussion between Karen McIntyre (VP, Global Site Alliances), Xoli Belgrave (Sr. Director, Head of Clinical Trial Diversity and Inclusion), Jamie Langley (Executive Director, Parexel Academy) and Dr. Lovie Negrin, CEO and Founder of Randomize now on how we can empower and leverage sites with the tools and training they need to more successfully recruit diverse patient populations for their studies. They talk about...
View this post
Enabling Successful Sites Ep. 3: Taking the complexity out of oncology trials June 28, 2024 10:25am
Oncology clinical trials present unique challenges for investigative sites, including complex trial designs, challenging eligibility criteria, and invasive procedures. In addition, the oversaturation of trials leads to competition for patients and experienced sites.
The third episode of Enabling Successful Sites features a discussion between Karen McIntyre (VP, Global Site Alliances), Mitch Carter (Assoc. Director, Global Site Alliances), and Angela Galindo, Vice President, Client Engage...
View this post
De-risking Drug Development | Episode 2: Focus on safety and efficacy and prove quickly that your product works June 19, 2024 11:00am
De-risking Drug Development is a five-part podcast series that explores the business-critical decisions that take place at each stage of the drug development process. We know that novel therapies often don’t meet their revenue expectations, but through informed decision-making, you can minimize risk and maximize the probability of commercial success.
In episode two we discuss the critical decision points in early phase development (phase I to IIa) that can ultimately determine the success of y...
View this post
De-risking Drug Development | Episode 1: How to drive value in pre-clinical development May 23, 2024 2:16pm